HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation
Regeneron, Mylan, and Biocon Settle in Aflibercept BPCIA Litigation
Federal Circuit Affirms Denial of Injunction Against Amgen in Aflibercept BPCIA Litigation
Amgen and Fresenius Settle Denosumab BPCIA Case
Federal Circuit Affirms Injunction Against Celltrion in Aflibercept BPCIA Litigation
FDA Accepts U.S. Biologics License Application for AVT06, Alvotech and Teva’s Proposed Aflibercept Biosimilar
FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes
HyClone Seeks to Quash Amgen’s Subpoena Issued in Denosumab BPCIA Litigation Against Fresenius
Federal Circuit Affirms Injunction Against Samsung and Formycon in Aflibercept BPCIA Litigation
Subscribe: Subscribe via RSS
Blogs
Firm/Org